two words "in solution" be added in the first sentence of 
Recommendation D: 
"This section covers experiments involving whole 
animals, both those in which the animal's genome has 
been altered by stable introduction of DNA in solution 
into the germ line (transgenic animals) and experiments 
involving viable recombinant-DNA-modif ied 
microorganisms tested on whole animals. 
Dr. McGarrity noted there was no motion on the table and asked 
whether the committee felt that final details of language could 
be worked out during the recess or whether, if closure were at 
hand, the issue could be dealt with before the recess. 
Dr. Neiman moved that the modifications to the NIH Guidelines, as 
stated by Dr. Gottesman be adopted. Dr. Erickson seconded the 
motion. 
Dr. Gartland asked for clarification of the wording of the first 
sentence of Recommendation D. Dr. Gottesman suggested the 
wording as presented on page 365, having been already moved for 
adoption, be discussed either before or after the recess and an 
amendment proffered. She reiterated the points previously made 
regarding changing the definition of "recombinant DNA" versus 
covering transgenic animals in a broader sense. 
Dr. McGarrity said the recess was in order and the committee 
adjourned for a brief recess. 
Dr. McGarrity called the committee back to order at 10:53 a.m. to 
continue the morning's discussion. He said there were two ways 
to proceed: (1) change the definition of "recombinant DNA" to 
make it more encompassing or inclusive of transgenic animals 
which would probably require Federal Register publication for 
public comment; or (2) adopting the recommendations of the 
working group with some modifications with the understanding that 
further changes could be made as the technology moves forward in 
the coming years. He noted Dr. Wyngaarden had expressed an 
interest that some body should be looking at the issue of trans- 
genic animals and, as Dr. Davis said earlier, the RAC at present 
is the most likely place for such discussions to take place. 
Dr. McGarrity called for a "sense of the committee" as to whether 
it is comfortable with the motion currently before it or if it 
would be inclined to technically overstep the bounds of the NIH 
Guidelines, possibly with the support of the Director, to say 
there may be some areas that it or IBCs should look at that 
technically do not come under the current definition of 
"recombinant DNA." The committee voted by show of hands to 
continue its discussion of the current motion before it regarding 
the recommendations of the Working Group on Transgenic Animals. 
[ 140 ] 
Recombinant DNA Research, Volume 13 
